Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Counterregulatory Response to Hypoglycemia in Type 1 Diabetes
NCT03704818Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Dapagliflozin 5mg with Placebo (2 arms). Primary endpoints: Glucagon Response to Hypoglycemia at 12 weeks, Epinephrine Response to Hypoglycemia at 12 weeks and 6 more. Started Oct 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03704818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704818.